and recommendation

StemCells, Inc. (STEM)
StemCells, Inc., a biopharmaceutical company, engages in the research, development, and commercialization of cell-based therapeutics and tools for use in stem cell-based research and drug discovery primarily in the United States. Its lead therapeutic product candidate, HuCNS-SC cells (purified human neural stem cells), is in development as a potential treatment for a range of central nervous system disorders. The company has conducted a Phase I clinical trial in Pelizaeus-Merzbacher disease, a fatal myelination disorder in children. It is also conducting a Phase I/II clinical trial in chronic spinal cord injury; and has initiated a Phase I/II clinical trial in dry age-related macular degeneration, as well as is pursuing preclinical studies in Alzheimers disease. In addition, the company markets a rage of proprietary cell culture products, research grade human cells, and antibody reagents under the SC Proven brand. The proprietary cell culture products include iSTEM, GS1-R, GS2-M, RHB-A, RHB-Basal, NDiff227, NDiff N2, and NDiff N27 supplements, as well as HEScGRO and ESGRO Complete; and antibody reagents comprise STEM24, STEM101, STEM121, and STEM123, which can be used for cell detection, isolation, and characterization. Further, StemCells is involved in developing and commercializing applications of its technologies to enable stem cell-based research. The company sells its tools and technologies products to researchers at academic institutions, pharmaceutical and biotechnology companies, and government laboratories. StemCells, Inc. was founded in 1988 and is headquartered in Newark, California.
- August 18, 2014 - 7:21pm | Earnings
- August 18, 2014 - 2:20pm | Earnings
- August 18, 2014 - 2:11pm | Earnings
- August 18, 2014 - 1:45pm | Earnings
- August 13, 2014 - 9:06pm | Clear and Present Dangers
- August 11, 2014 - 11:00am | Financings
- August 10, 2014 - 1:04pm | Clear and Present Dangers
- August 5, 2014 - 9:20am | Research Notes
- August 4, 2014 - 6:52pm | Pharma Deals
- August 4, 2014 - 9:44am | Research Notes
- August 3, 2014 - 10:30pm | Earnings Q2
- July 30, 2014 - 7:37am | Regulatory
- July 28, 2014 - 10:15am | IP & Patents
- July 28, 2014 - 9:37am | Research Notes
- July 25, 2014 - 10:09am | Out and About
- July 24, 2014 - 8:51am | Research Notes
- July 22, 2014 - 9:54am | Regulatory
- July 21, 2014 - 7:32am | Research Notes
- July 17, 2014 - 10:46am | Regulatory
- July 16, 2014 - 10:55am | Out and About